Resveratrol (3,5,4′-trihydroxystilbene) is a polyphenolic phytoalexin. It is a stilbenoid, a derivate of stilbene, and is produced in plants with the help of the enzyme stilbene synthase. It exists as cis-(Z) and trans-(E) isomers. The trans- form can undergo isomerisation to the cis- form when heated or exposed to ultraviolet irradiation. In a 2004 issue of Science, Dr. Sinclair of Harvard University said resveratrol is not an easy molecule to protect from oxidation. It has been claimed that it is readily degraded by exposure to light, heat, and oxygen. However, studies find that Trans-resveratrol undergoes negligible oxidation in normal atmosphere at room temperature.
Science-backed PDE/ADE, OEL & OEB derivation by certified toxicologists with ex-agency experts -
Resveratrol
Drug Overview
What is Resveratrol?
To derive PDE/ADE, OEL, and OEB values, Masuu Global follows a scientifically justified, risk-based toxicological assessment approach in accordance with internationally recognized guidelines and industry best practices that are widely accepted by regulatory authorities, including European Medicines Agency (EMA), Pharmaceutical Inspection Co-operation Scheme (PIC/S), and Agência Nacional de Vigilância Sanitária (ANVISA).
Request Your Assessment
Add this compound to your inquiry list and our team will follow up with full documentation, pricing, and licensing terms.
View Inquiry List →Full OEL derivation · ADE/PDE value · Control band assignment · All cited references · EMA / ICH Q9 compliance
Regulatory Framework
Assessment Methodology
Masuu Global follows a scientifically justified, risk-based toxicological approach aligned with internationally recognized guidelines accepted by EMA, PIC/S, and ANVISA.
EMA – Guideline on Setting Health-Based Exposure Limits (HBELs)
Provides the framework for establishing scientifically justified PDE/ADE values for use in shared manufacturing facilities.
PIC/S – Shared Facilities and Contamination Control Guidance
Supports the application of HBEL-based approaches for cross-contamination prevention and cleaning validation.
ICH Q9 – Quality Risk Management
Provides a structured methodology for risk identification, assessment, control, communication, and review.
ICH M7 – Assessment and Control of DNA-Reactive (Mutagenic) Impurities (where applicable)
Applied for compounds with potential mutagenic or genotoxic concerns.
Risk-Based Toxicological Assessment
Comprehensive evaluation of available toxicological and pharmacological data, including NOAEL, LOAEL, BMDL, pharmacological potency, carcinogenicity, reproductive and developmental toxicity, sensitization potential, and target organ toxicity.
Weight-of-Evidence (WoE) Approach
Integration and critical review of all relevant data sources, including non-clinical studies, clinical studies, human exposure data, pharmacological information, post-marketing safety data, and structure–activity relationship (SAR/QSAR) assessments.
How We Work
Report Preparation Process
Every assessment moves through a rigorous five-stage workflow — from data gathering to regulatory-ready delivery.
Comprehensive Data Review
Assessment of pharmacology, toxicology, clinical data, literature, and available regulatory information.
Scientific Evaluation
Identification of critical endpoints and selection of appropriate exposure limits.
PDE / HBEL Derivation
Transparent and scientifically justified calculations aligned with global toxicological principles.
Ex-Agency Expert Review (Our Differentiator)
Reports are reviewed with an ex-agency perspective, bringing regulatory expectations, inspection readiness, and practical implementation into every assessment.
Final Report Delivery
Regulatory-ready reports with scientific rationale, calculations, and clear recommendations by certified toxicologists (ERT, UKRT and DABT).
Ex-Agency Advantage
Why Masuu Global?
Our ex-agency toxicologists bring a practical regulatory perspective that transforms how assessments are built, reviewed, and defended.
Regulatory expectation–driven assessments aligned with how authorities actually evaluate submissions.
Inspection-ready reports — scientifically defensible and audit-prepared from day one.
Faster review cycles with direct decision support from certified toxicologists (ERT, UKRT, DABT).
Practical implementation recommendations that translate science into actionable contamination control.
Reduced internal effort — offload complex assessments without sacrificing quality or defensibility.
Global reach across PDE/ADE, HBEL, OEL, OEB, cleaning validation, and impurity assessments.
Ready to request your assessment?
Add this compound to your inquiry list, or browse our full database of 3,000+ molecules.
Frequently Asked Questions
Resveratrol is a naturally occurring stilbene polyphenol. Its precise grade, formulation, and handling context should be confirmed from the applicable technical documentation. A toxicological assessment should use reliable evidence for the specific material and avoid assuming properties or exposure risks that are not established by the available data.
A PDE or ADE sets a health-based limit on daily exposure to Resveratrol from residual carryover. Manufacturers use it in cross-contamination risk assessments and cleaning validation when the compound is processed in shared equipment or facilities. Whether a report is required depends on how it is used and on applicable regulatory expectations.
Potential carryover of Resveratrol is evaluated by combining a scientifically justified health-based exposure limit with process and equipment information. The evaluation may consider shared surfaces, product sequence, batch factors, cleaning procedures, sampling locations, and analytical methods. The PDE or ADE helps establish a health-based criterion, while the overall contamination-control strategy determines how residues are prevented, detected, and managed.
New safety data relevant to Resveratrol should be evaluated for reliability, relevance, and whether it changes the critical endpoint or the interpretation of existing evidence. If the new information materially affects the assessment, the PDE, ADE, OEL, or banding rationale may need to be updated. The decision and its basis should be documented, including any implications for cleaning validation, containment, and worker-protection measures.
The assessment of Resveratrol should consider the reliable evidence available for the specific substance, including repeat-dose toxicity, genotoxicity, reproductive and developmental endpoints, and pharmacological effects where relevant. The evaluator should identify the critical effect, assess study quality and relevance, and document data gaps. Conclusions should remain proportionate to the evidence rather than assume unsupported hazards or safety.
An OEL is derived by reviewing the toxicological and occupational health evidence, identifying the critical effect, and applying a recognized assessment methodology. The final value should come with a documented rationale, clearly stated units, and the exposure duration it applies to, so it can be used confidently in workplace risk assessment.
An OEB places Resveratrol in a hazard category using a defined banding framework and the available toxicological evidence. Criteria and numerical ranges differ between frameworks, so the report should identify the system used. The band then guides the level of containment and handling controls suited to the compound.
An OEL assessment for Resveratrol provides a health-based reference for evaluating occupational exposure. Employers can use it alongside exposure monitoring, process knowledge, engineering controls, containment, and appropriate work practices. The assessment should consider relevant tasks such as dispensing, transfer, sampling, equipment cleaning, and maintenance, while recognizing that a numerical limit alone does not replace a complete occupational hygiene program.
An occupational exposure band for Resveratrol can support preliminary hazard communication and control selection when a formal OEL is unavailable or when a banding framework is used internally. However, an OEB is not automatically equivalent to a substance-specific OEL. The report should identify the banding method and its limitations, and the organization should avoid treating a band as a measured or formally derived exposure limit.
The physical form and handling conditions for Resveratrol can affect the likelihood of workplace exposure, although they do not by themselves determine toxicity. Powder handling may create different inhalation concerns from a solution or a contained liquid transfer. The assessment should consider dustiness, particle characteristics where known, process conditions, containment, and the tasks performed, using substance-specific evidence wherever available.
Masuu Global follows a scientifically justified, risk-based approach aligned with internationally recognized guidance accepted by regulators, including the EMA guideline on health-based exposure limits, PIC/S guidance on shared facilities and contamination control, ICH Q9 quality risk management, and ICH M7 where applicable.
Use the Request Your Assessment option on this page and add Resveratrol to your inquiry list. The Masuu Global team will follow up with full documentation, pricing, and licensing terms. Mention your intended use and market so the scope of the report can be confirmed.
